1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

No US Filing Until 2026? Aurobindo’s CuraTeQ Inks Ustekinumab Deal

Arrangement With US-Based BioFactura Provides For Broad Global Rights

 
• By Dean Rudge

With J&J’s blockbuster Stelara treatment for autoimmune diseases scheduled to fall to biosimilar competition in the coming years, Aurobindo’s biosimilars business has stepped up to get a piece of the action, striking a deal with BioFactura.

Strategic Partnership concept on the gearwheels - Illustration
• Source: Shutterstock

Aurobindo Pharma Limited’s biosimilars subsidiary CuraTeQ Biologics has entered into an exclusive commercialization and manufacturing agreement with BioFactura, Inc. for the US-based firm’s BFI-751 proposed biosimilar to Johnson & Johnson’s Stelara (ustekinumab) – a candidate that the firms admit will not be ready for filing in major developed markets until at least 2026, with rival filings already beginning to reach regulators in markets like the US and Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.